Randomized Trialhigh evidence
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.
Lancet (London, England)·March 14, 2026·PMID 41796601
Why it mattersTGCT is a rare, locally aggressive tumour with few systemic options. Pimicotinib offers a new, effective oral therapy with a favorable safety profile, addressing an unmet need for patients who are not surgical candidates.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled